Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644673 | 0.86 | TSHR (0.48) | SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19 | |
| SCHEMBL9615023 | 0.86 | CYP4F2 (0.42) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11147758 | 0.82 | TDP1 (0.41) | PPARGPPARA | |
| SCHEMBL675062 | 0.82 | ALDH1A1 (0.44) | PPARGPPARATSHRLMNALTA4H | |
| SCHEMBL5566637 | 0.79 | RCE1 (0.51) | SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19 | |
| SCHEMBL6040933 | 0.79 | LTA4H (0.38) | PPARGPPARATSHRLMNAL3MBTL1 | |
| SCHEMBL1412775 | 0.79 | ALDH1A1 (0.50) | PPARGPPARACYP2D6LMNASLC6A2 | |
| SCHEMBL10869937 | 0.78 | ALDH1A1 (0.46) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9019164 | 0.78 | SLC1A3 (0.41) | SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19 | |
| SCHEMBL9019170 | 0.78 | SLC1A3 (0.41) | SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668130-B2 | Formulation for targeting cancer in humans and canines using chlorotoxin | RAMANA VIVEKANANDA (US) | 2020-06-02 | — | — | US | disclosed |
| US-10668113-B2 | Formulation for targeting cancer in humans and canines using venom | RAMANA VIVEKANANDA (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180280449-A1 | FORMULATION FOR TARGETING CANCER IN HUMANS AND CANINES USING VENOM | RAMANA VIVEKANANDA (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180280473-A1 | FORMULATION FOR TARGETING CANCER IN HUMANS AND CANINES USING CHLOROTOXIN | RAMANA VIVEKANANDA (US) | 2018-10-04 | — | — | US | disclosed |
| EP-1434595-A1 | STABLE SOLUTIONS OF PEPTIDE COPPER COMPLEXES AND COSMETIC AND PHARMACEUTICAL FORMULATIONS PRODUCED THEREFROM | PROCYTE CORPORATION (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030148927-A1 | Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom | PROCYTE CORPORATION | 2003-08-07 | — | — | US | disclosed |
| WO-2003030926-A1 | STABLE SOLUTIONS OF PEPTIDE COPPER COMPLEXES AND COSMETIC AND PHARMACEUTICAL FORMULATIONS PRODUCED THEREFROM | PROCYTE CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-0743359-B1 | Aqueous floor cleaning agent in high concentration | HENKEL ECOLAB GMBH & CO OHG (DE) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148927-A1 | Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom | THEM6, NOTUM, ORMDL3 | PPARG 3041/4885PPARA 2094/4885SLC1A3 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.